CARD11 alteration as a candidate biomarker of skin cutaneous melanoma treated with immune checkpoint blockade.

ABSTRACT:

Background

Immune checkpoint inhibitors (ICIs) can be problematic, including a lack of sustained clinical response, in the treatment of skin cutaneous melanoma (SKCM) patients; therefore, predictive biomarkers are urgently needed. Recently, gene mutations identified by melanoma genomic analysis have shown great predictive potential.

Methods

We collected an immunotherapy cohort and The Cancer Genome Atlas (TCGA)-SKCM cohort from published studies and tested the predictive function of the CARD11 mutation. We then further studied the association between the CARD11 mutation and tumor immunogenicity by studying related genes and pathways in the tumor microenvironment (TME).

Results

In the immunotherapy and TCGA-SKCM cohorts, patients with CARD11-mutant (MT) tumors had long

SUBMITTER: Si Y 

PROVIDER: S-EPMC7847528 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature